Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 8;10(12):2538.
doi: 10.3390/jcm10122538.

Management of Cataract in Patients with Age-Related Macular Degeneration

Affiliations
Review

Management of Cataract in Patients with Age-Related Macular Degeneration

Hemal Mehta. J Clin Med. .

Abstract

Cataract and age-related macular degeneration (AMD) are two of the most common eye diseases of aging. This review addresses the pre-operative, intra-operative, and post-operative considerations in managing cataract in patients with age-related macular degeneration. Surgery for visually significant cataracts in patients with AMD can substantially improve the quality of life and reduce the risk of falls. Pre-operative optical coherence tomography is now recommended where possible to identify pre-existing macula disease. Careful counselling of patients is required before cataract surgery, especially with respect to the expected visual outcome, intraocular lens choice and potential risks of surgery. Real-world data has suggested 6 months of intravitreal anti-VEGF therapy for neovascular AMD before cataract surgery is compatible with optimum long-term visual outcomes. Patients receiving intravitreal therapy for neovascular AMD should be advised of the slightly higher risk of intraoperative complications and the surgeon should be prepared to manage these during the operation. During cataract surgery, unnecessary light exposure should be avoided to reduce phototoxicity. Careful planning of intravitreal therapy for neovascular AMD just before cataract surgery allows the eye greater recovery time in the post-operative period before further planned intravitreal therapy.

Keywords: age-related macular degeneration; cataract surgery; clinical trials; real-world evidence.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

Cited by

References

    1. Steinmetz J.D., Bourne R.R., Briant P.S., Flaxman S.R., Taylor H.R., Jonas J.B., Abdoli A.A., Abrha W.A., Abualhasan A., Abu-Gharbieh E.G., et al. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health. 2021;9:e144–e160. doi: 10.1016/S2214-109X(20)30489-7. - DOI - PMC - PubMed
    1. Weill Y., Hanhart J., Zadok D., Smadja D., Gelman E., Abulafia A. Patient Management Modifications in Cataract Surgery Candidates Following Incorporation of Routine Preoperative Macular optical coherence tomography. J. Cataract Refract. Surg. 2020;47:78–82. doi: 10.1097/j.jcrs.0000000000000389. - DOI - PubMed
    1. Forooghian F., Agron E., Clemons T.E., Ferris F.L., 3rd, Chew E.Y., Age-Related Eye Disease Study Research Group Visual acuity outcomes after cataract surgery in patients with age-related macular degeneration: Age-related eye disease study report no. 27. Ophthalmology. 2009;116:2093–2100. doi: 10.1016/j.ophtha.2009.04.033. - DOI - PMC - PubMed
    1. Age-Related Eye Disease Study 2 Research Group. Huynh N., Nicholson B.P., Agron E., Clemons T.E., Bressler S.B., Rosenfeld P.J., Chew E.Y. Visual acuity after cataract surgery in patients with age-related macular degeneration: Age-related eye disease study 2 report number 5. Ophthalmology. 2014;121:1229–1236. doi: 10.1016/j.ophtha.2013.12.035. - DOI - PMC - PubMed
    1. Rosenfeld P.J., Shapiro H., Ehrlich J.S., Wong P., MARINA and ANCHOR Study Groups Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Am. J. Ophthalmol. 2011;152:793–798. doi: 10.1016/j.ajo.2011.04.025. - DOI - PubMed

LinkOut - more resources